|
High-yield prefusion stabilized hPIV3 antigens for vaccine and diagnostic development
This technology uses novel amino acid substitutions to stabilize the human parainfluenza virus 3 fusion protein, enabling its use as a more effective vaccine antigen and diagnostic reagent by improving protein stability and expression.
Background
Human parainfluenza virus 3 (hPIV3) is a prevalent respiratory pathogen causing severe illness...
|
|
Engineered hantavirus glycoprotein complexes for enhanced vaccines, antibody discovery, and diagnostic applications
This technology uses engineered hantavirus glycoproteins stabilized in their prefusion form to create more effective vaccines, antibody therapies, and diagnostic tools, improving immune response, production efficiency, and shelf life for hantavirus prevention and detection.
Background
Hantaviruses are a group of zoonotic viruses that cause severe...
|
|
Engineered prefusion-stabilized RSV fusion proteins and nucleic acids for enhanced vaccines and diagnostics
This technology uses engineered RSV prefusion proteins with specific mutations to boost stability, expression, and shelf life, enabling more effective and affordable RSV vaccines, treatments, and diagnostics in both protein and nucleic acid (e.g., mRNA) formats.
Background
Respiratory Syncytial Virus (RSV) is a leading cause of severe respiratory...
|
|
OPG153-based vaccine for targeted mpox immunization
Background
The global re-emergence of monkeypox virus (MPXV) has created a critical need for effective and well-tolerated vaccines to prevent infection, limit disease severity, and reduce transmission. As an orthopoxvirus related to smallpox, mpox presents a unique public health challenge, especially for immunocompromised populations.
Current...
|
|
Glycoprotein engineering for hemorrhagic fever virus vaccines
Scientists stabilized the Crimean-Congo hemorrhagic fever virus glycoprotein complex to study its structure and develop a potential vaccine. This complex elicits an immune response and sheds light on the virus's entry mechanism.
Background
Crimean-Congo hemorrhagic fever virus (CCHFV) is a serious threat to human health, with mortality rates ranging...
|
|
Stabilized coronavirus spike proteins for enhanced vaccine efficacy
Engineered proteins with stabilized coronavirus spike protein ectodomains enhance immune response and are useful in diagnostics, screening, and vaccines against coronaviruses like SARS-CoV-2 by maintaining prefusion conformation, potentially producing cross-reactive antibodies.
Background
The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has...
|
|
Engineered chimeric fusion proteins
Enhancing stability and expression for improved vaccines and diagnostics in hMPV and RSV
The invention describes engineered chimeric F proteins combining sequences from human metapneumovirus (hMPV) and respiratory syncytial virus (RSV) to enhance stability and expression. These proteins are useful in vaccines, diagnostics, and antibody screening.
Background
Respiratory...
|
|
Monoclonal antibodies for the conserved feature of the coronavirus spike protein
The invention describes monoclonal antibodies targeting conserved epitopes on the S2 domain of coronavirus spike proteins, potentially useful for preventing or treating infections by inhibiting viral entry. These antibodies could aid in therapeutic formulations against coronaviruses like SARS-CoV-2, SARS-CoV, and MERS-CoV.
Background
The emergence...
|
|
Producing modified lipid A bacterial vaccine components
Engineered bacteria are designed to produce modified lipid A with reduced toxicity and either polypeptide or polysaccharide antigens, which can be used in vaccines to elicit targeted immune responses.
Background
The challenge of developing effective vaccines against bacterial infections lies in the dual necessity of eliciting a robust immune response...
|
|
Engineered polypeptides for enhanced integrin binding and antigen delivery
Engineered recombinant Invasin polypeptides have been modified to enhance integrin binding and resist intestinal proteolysis, facilitating effective oral delivery of therapeutics, such as vaccines, by targeting M cells in the gut for improved immune responses.
Background
The challenge of delivering therapeutics such as vaccines effectively across...
|
